The Inventor's Inventor: An Interview With Tom Fogarty
For more than 40 years, Tom Fogarty has played a central role in global medical device innovation. Following a fruitful relationship with Edwards, which saw the development of the Fogarty embolectomy catheter and artficial heart valve, Fogarty went on to launch his own companies, including General Surgical, CTS, and Biopsys, to name just a few. In this interview, taken from a lecture series at Stanford University, Fogarty talks about his early days as a device innovator and how medical device innovation has changed today.
by David Cassak
The archetypal physician entrepreneur, Thomas Fogarty, MD, has been a driving force in medical device innovation for nearly 40 years. From his first device, invented when he was still in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
